182 related articles for article (PubMed ID: 18396750)
1. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
2. A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.
Galati G; Gentilucci UV; Sansoni I; Spataro S; Di Matteo FM; Zardi EM; Grasso RF; Avvisati G; Afeltra A; Picardi A
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):233-6. PubMed ID: 19212214
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
4. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
6. Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Gianotti R; Charles H; Hymes K; Chandarana H; Sigal S
World J Gastroenterol; 2014 Oct; 20(39):14495-9. PubMed ID: 25339837
[TBL] [Abstract][Full Text] [Related]
7. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
[TBL] [Abstract][Full Text] [Related]
8. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
9. Concomitant diagnosis of myeloproliferative neoplasm and non-Hodgkin's lymphoma in a patient with portal vein thrombosis.
Papageorgiou MV; Alexopoulou A; Kontopidou F; Filiotou A; Koskinas J; Pectasides D
Anticancer Res; 2011 Apr; 31(4):1467-9. PubMed ID: 21508404
[TBL] [Abstract][Full Text] [Related]
10. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
[No Abstract] [Full Text] [Related]
12. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
15. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
[No Abstract] [Full Text] [Related]
16. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
[TBL] [Abstract][Full Text] [Related]
17. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
18. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
19. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
